Holen Sie sich die Stockscreener-App
82.76
0.06%
-0.05
Handel nachbörslich:
83.01
0.25
+0.30%
Schlusskurs vom Vortag:
$82.81
Offen:
$82.97
24-Stunden-Volumen:
93,722
Relative Volume:
1.67
Marktkapitalisierung:
$2.56B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-32.61M
KGV:
-108.87
EPS:
-0.7602
Netto-Cashflow:
-
1W Leistung:
+5.24%
1M Leistung:
+45.32%
6M Leistung:
+84.03%
1J Leistung:
+122.47%
1-Tages-Spanne:
$80.25
$84.50
1-Wochen-Bereich:
$78.20
$86.53
52-Wochen-Spanne:
$31.00
$86.53
Belite Bio Inc Adr Stock (BLTE) Company Profile
Firmenname
Belite Bio Inc Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie BLTE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| BLTE | 82.76 | 2.56B | 0 | -32.61M | 0 | -0.7602 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-14 | Eingeleitet | Maxim Group | Buy |
| 2023-07-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-26 | Eingeleitet | SVB Securities | Outperform |
| 2022-08-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-01 | Eingeleitet | The Benchmark Company | Buy |
Belite Bio Inc Adr Aktie (BLTE) Neueste Nachrichten
FY2024 EPS Estimates for Belite Bio Lowered by HC Wainwright - Defense World
Belite Bio, Inc (NASDAQ:BLTE) Short Interest Down 13.5% in October - MarketBeat
Belite Bio (NASDAQ:BLTE) Given New $110.00 Price Target at Maxim Group - MarketBeat
Belite Bio stock soars to all-time high of $84.2 amid robust gains - Investing.com UK
Earnings call: Belite Bio reports progress in Tinlarebant trials By Investing.com - Investing.com Australia
Belite Bio shares target boosted, retains buy rating on trial progress - Investing.com
Earnings call: Belite Bio reports progress in Tinlarebant trials - Investing.com
Belite Bio Advances in Retinal Disease Trials - TipRanks
Belite Bio Advances in Tinlarebant Trials, Appoints New CMO - TipRanks
Belite Bio Advances Eye Disease Trials, Posts $109M Cash Position in Q3 Update | BLTE Stock News - StockTitan
Riot Platforms Inc (RIOT-Q) QuotePress Release - The Globe and Mail
Belite Bio (BLTE) Set to Announce Earnings on Tuesday - MarketBeat
Belite Bio (BLTE) Sets Q3 2024 Earnings Call: Key Updates on Retinal Disease Pipeline | BLTE Stock News - StockTitan
Belite Bio stock soars to all-time high of $70.4 amid robust growth - Investing.com
Belite Bio (NASDAQ:BLTE) Sees Strong Trading VolumeStill a Buy? - MarketBeat
Belite Bio Offers New Warrant Opportunities to Investors - TipRanks
Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds - ForexTV.com
Nike Inc (NKE-N) QuotePress Release - The Globe and Mail
Belite Bio stock soars to all-time high of $67.6 amid robust gains - Investing.com UK
TSX Smallcap Index (TXTW) QuotePress Release - The Globe and Mail
Belite Bio (NASDAQ:BLTE) Hits New 52-Week HighHere's What Happened - MarketBeat
Belite Bio (NASDAQ:BLTE) Trading Up 4%Should You Buy? - MarketBeat
Belite Bio (NASDAQ:BLTE) Hits New 12-Month HighHere's Why - MarketBeat
Belite Bio stock soars to all-time high of $56.62 By Investing.com - Investing.com UK
Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting - The Bakersfield Californian
First patient dosed at the Tokyo Medical Center by Belite Bio in Phase 2/3 DRAGON II clinical trial - Ophthalmology Times
Belite Bio (NASDAQ:BLTE) Sets New 12-Month HighStill a Buy? - MarketBeat
Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit - The Bakersfield Californian
Week in ReviewOctober 5, 2024 - Ophthalmology Times
Belite Bio (NASDAQ:BLTE) Hits New 1-Year High at $50.69 - MarketBeat
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - GlobeNewswire
Armistice Capital LLC Invests $6.76 Million in Belite Bio, Inc (NASDAQ:BLTE) - MarketBeat
Servicenow Inc (NOW-N) QuotePress Release - The Globe and Mail
International companies to host live webcasts at Deutsche - GlobeNewswire
Belite Bio, Inc (NASDAQ:BLTE) Short Interest Down 5.1% in August - MarketBeat
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 - GlobeNewswire Inc.
Belite Bio (NASDAQ:BLTE) Rating Reiterated by HC Wainwright - Defense World
Belite Bio shares hold buy rating, steady target on trial progress - Investing.com
Belite Bio's (BLTE) Buy Rating Reiterated at HC Wainwright - MarketBeat
Belite Bio Announces First Patient Dosed in Phase 2/3 - GlobeNewswire
Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease - StockTitan
Belite Bio Welcomes New Chief Medical Officer - TipRanks
Belite Bio to Participate in Three Upcoming Investor Conferences - StockTitan
Belite Bio, Inc (NASDAQ:BLTE) Short Interest Down 9.6% in August - MarketBeat
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer - ForexTV.com
Belite Bio (NASDAQ:BLTE) Sees Large Volume Increase - MarketBeat
Short Interest in Belite Bio, Inc (NASDAQ:BLTE) Expands By 10.7% - MarketBeat
Belite Bio (NASDAQ:BLTE) Trading Down 1.8% - MarketBeat
HC Wainwright Analysts Decrease Earnings Estimates for Belite Bio, Inc (NASDAQ:BLTE) - Defense World
FY2024 EPS Estimates for Belite Bio, Inc Lowered by Analyst (NASDAQ:BLTE) - Defense World
Golden Ocean Group (NASDAQ:GOGL) Downgraded to Sell at StockNews.com - Defense World
Finanzdaten der Belite Bio Inc Adr-Aktie (BLTE)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):